0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Recognition of Illness Associated With Exposure to Chemical Agents—United States, 2003 FREE

JAMA. 2003;290(17):2247-2248. doi:10.1001/jama.290.17.2247.
Text Size: A A A
Published online

RECOGNITION OF ILLNESS ASSOCIATED WITH EXPOSURE TO CHEMICAL AGENTS—UNITED STATES, 2003

MMWR. 2003;52:938-940

1 table omitted

Since September 11, 2001, concern has increased about potential terrorist attacks involving the use of chemical agents. In addition, recent cases involving intentional or inadvertent contamination of food with chemicals have highlighted the need for health-care providers and public health officials to be alert for patients in their communities who have signs and symptoms consistent with chemical exposures.1-3 For example, in February 2003, a Michigan supermarket worker was charged with intentionally contaminating 200 lbs. of meat with a nicotine-containing insecticide.3 Although intentional release of chemical agents might be an overt event (i.e., one whose nature reveals itself), such as release of a nerve agent in a subway or a large explosion of a chemical container, a chemical release might instead be a covert event (i.e., an unrecognized release in which the presence of ill persons might be the first sign of an exposure), such as deliberate contamination of food, water, or a consumer product. To increase the likelihood that health-care providers will recognize a chemical-release–related illness and that public health authorities will implement the appropriate emergency response and public health actions, CDC identified examples of chemical-induced illness and created appropriate guidance for health-care providers and public health personnel. This report summarizes the epidemiologic clues and clinical signs or patterns of illness that might suggest covert release of a chemical agent. CDC is working to develop national surveillance capabilities for detecting chemical-release–related illnesses.

A covert release of a chemical agent might not be identified easily for at least five reasons. First, symptoms of exposure to some chemical agents (e.g., ricin) might be similar to those of common diseases (e.g., gastroenteritis). Second, immediate symptoms of certain chemical exposures might be nonexistent or mild despite the risk for long-term effects (e.g., neurocognitive impairment from dimethyl mercury, teratogenicity from isotretinoin, or cancer from aflatoxin). Third, exposure to contaminated food, water, or consumer products might result in reports of illness to health-care providers over a long period and in various locations. Fourth, persons exposed to two or more agents might have symptoms not suggestive of any one chemical agent (i.e., a mixed clinical presentation). Finally, health-care providers might be less familiar with clinical presentations suggesting exposure to chemical agents than they are with illnesses that are treated frequently.

Epidemiologic Clues Suggesting a Covert Chemical Release

Epidemiologic clues that might suggest the covert release of a chemical agent include (1) an unusual increase in the number of patients seeking care for potential chemical-release–related illness; (2) unexplained deaths among young or healthy persons; (3) emission of unexplained odors by patients; (4) clusters of illness in persons who have common characteristics, such as drinking water from the same source; (5) rapid onset of symptoms after an exposure to a potentially contaminated medium (e.g., paresthesias and vomiting within minutes of eating a meal); (6) unexplained death of plants, fish, or animals (domestic or wild); and (7) a syndrome (i.e., a constellation of clinical signs and symptoms in patients) suggesting a disease associated commonly with a known chemical exposure (e.g., neurologic signs or pinpoint pupils in eyes of patients with a gastroenteritis-like syndrome or acidosis in patients with altered mental status).

Various chemical agents could be used as covert weapons, and the actual clinical syndrome will vary depending on the type of agent, the amount and concentration of the chemical, and the route of the exposure. However, certain clinical presentations might be more common with a covert chemical release. Certain syndromes are associated with groups of chemical agents with similar toxic properties that have been used previously, have high toxicity, or are easily available.4-10

Reported by:

M Patel, MD, J Schier, MD, M Belson, MD, C Rubin, DVM, P Garbe, DVM, Div of Environmental Hazards and Health Effects; J Osterloh, MD, Div of Laboratory Sciences, National Center for Environmental Health, CDC.

CDC Editorial Note:

Health-care providers, public health agencies, and poison control centers might be the first to recognize illness, treat patients, and implement the appropriate emergency response to a chemical release. Familiarity with general characteristics of a covert chemical release and recognition of epidemiologic clues and syndromic presentations of chemical agent exposures could improve recognition of these releases and might reduce further morbidity and mortality.

Public health agencies and health-care providers might render the most appropriate, timely, and clinically relevant treatment possible by using treatment modalities based on syndromic categories (e.g., burns, respiratory depression, neurologic damage, and shock). Treating exposed persons by clinical syndrome rather than by specific agent probably is the most pragmatic approach to the treatment of illness caused by chemical exposures.

State and local health departments should educate health-care providers to recognize unusual illnesses that might indicate release of a chemical agent. Strategies for responding to intentional chemical releases include (1) providing information or reminders to health-care providers and clinical laboratories; (2) encouraging reporting of acute poisonings to local poison control centers, which can guide patient management and facilitate notification of the proper health agencies, and to the local or state health department; (3) initiating surveillance for incidents that potentially involve the covert release of a chemical agent; (4) implementing the capacity to receive and investigate any report of such an event; (5) implementing appropriate protocols, including potentially accessing the Laboratory Response Network for Bioterrorism, to collect and transport specimens and to store them appropriately before laboratory analysis; (6) reporting immediately to CDC and local law enforcement if the results of an investigation suggest the intentional release of a chemical agent; and (7) requesting CDC assistance when necessary.

To begin developing national surveillance capabilities for detecting chemical-release–related illnesses, CDC is collaborating with the American Association of Poison Control Centers to use its Toxic Exposure Surveillance System to identify index cases, evolving patterns, or emerging clusters of hazardous exposures. Identification of early markers for chemical releases (e.g., characteristic symptom complexes, temporal and regional increases in hospitalizations, or sudden increases in case frequency or severity) will enable public health authorities to respond quickly and appropriately to an intentional chemical release.

CDC materials for emergency and health-care personnel, including a list of chemical agents and biologic toxins and their expected clinical syndromes, are available at http://www.bt.cdc.gov/agent/agentlistchem.asp. Additional information about responding to chemical attacks is available from the U.S. Army Medical Research and Materiel Command at http://www.biomedtraining.org/progmat.htm, the U.S. Army Medical Research Institute of Chemical Defense at http://ccc.apgea.army.mil, and CDC and the Agency for Toxic Substances and Disease Registry at http://www.atsdr.cdc.gov/mhmi.html.

References: 10 available

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
JAMAevidence.com


Exposure